These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3583391)

  • 1. A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms.
    Mehnert WH; Haas JF; Kittelmann B; Staneczek W; Möhner M; Kaldor JM; Day NE
    IARC Sci Publ; 1986; (78):203-21. PubMed ID: 3583391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide.
    Haas JF; Kittelmann B; Mehnert WH; Staneczek W; Möhner M; Kaldor JM; Day NE
    Br J Cancer; 1987 Feb; 55(2):213-8. PubMed ID: 3814491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia following chemotherapy for breast cancer.
    Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
    Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia following chemotherapy for ovarian cancer.
    Kaldor JM; Day NE; Pettersson F; Clarke EA; Pedersen D; Mehnert W; Bell J; Høst H; Prior P; Karjalainen S
    N Engl J Med; 1990 Jan; 322(1):1-6. PubMed ID: 2104664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second malignant neoplasms among long-term survivors of ovarian cancer.
    Travis LB; Curtis RE; Boice JD; Platz CE; Hankey BF; Fraumeni JF
    Cancer Res; 1996 Apr; 56(7):1564-70. PubMed ID: 8603403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects.
    Reichman BS; Green KB
    J Natl Cancer Inst Monogr; 1994; (16):125-9. PubMed ID: 7999454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of leukemia associated with the first course of cancer treatment: an analysis of the Surveillance, Epidemiology, and End Results Program experience.
    Curtis RE; Hankey BF; Myers MH; Young JL
    J Natl Cancer Inst; 1984 Mar; 72(3):531-44. PubMed ID: 6583439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risk factors and second primary malignancies among women with breast cancer.
    Trentham-Dietz A; Newcomb PA; Nichols HB; Hampton JM
    Breast Cancer Res Treat; 2007 Oct; 105(2):195-207. PubMed ID: 17186360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukemia after alkylating-agent therapy of ovarian cancer.
    Reimer RR; Hoover R; Fraumeni JF; Young RC
    N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian function and childbearing issues in breast cancer survivors.
    Gadducci A; Cosio S; Genazzani AR
    Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan.
    Lee KD; Chen SC; Chan CH; Lu CH; Chen CC; Lin JT; Chen MF; Huang SH; Yeh CM; Chen MC
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2647-55. PubMed ID: 18843006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia incidence following primary breast carcinoma treatment.
    Kaplan HG; Malmgren JA; Atwood M
    Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second primary tumours among survivors of childhood cancer treated with anticancer drugs.
    Hawkins MM
    IARC Sci Publ; 1986; (78):231-52. PubMed ID: 3473036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.